Patents by Inventor Billy G. Hudson

Billy G. Hudson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • &agr;-3 chain type IV collagen polynucleotides
    Patent number: 6277558
    Abstract: An isolated and substantially pure polynucleotide encoding 238 amino acids of the carboxy terminal end of the triple helical domain and all 233 amino acids of the carboxy terminal noncollageneous domain of the bovine &agr;3 chain of type IV collagen. An isolated and substantially pure polynucleotide encoding 218 amino acids of the carboxy terminal noncollagenous domain of the human &agr;3 chain of type IV collagen. Such polynucleotides are useful to express large amounts of proteins in vectors and such expressed proteins are useful to detect Goodpasture antibodies in blood and to remove Goodpasture antibodies from the bloodstream of patients suffering from Goodpasture syndrome.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: August 21, 2001
    Assignee: Kansas University Medical Center
    Inventor: Billy G. Hudson
  • Advanced glycation end-product intermediaries and post-amadori inhibition
    Patent number: 6228858
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: May 8, 2001
    Assignee: University of Kansas Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • Alpha-3 chain type IV collagen polypeptides
    Patent number: 6007980
    Abstract: An isolated and substantially pure polynucleotide encoding 238 amino acids of the carboxy terminal end of the triple helical domain and all 233 amino acids of the carboxy terminal noncollageneous domain of the bovine .alpha.3 chain of type IV collagen. An isolated and substantially pure polynucleotide encoding 218 amino acids of the carboxy terminal noncollagenous domain of the human .alpha.3 chain of type IV collagen. Such polynucleotides are useful to express large amounts of proteins in vectors and such expressed proteins are useful to detect Goodpasture antibodies in blood and to remove Goodpasture antibodies from the bloodstream of patients suffering from Goodpasture syndrome.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: December 28, 1999
    Assignees: Yale University, University of Kansas Medical Center
    Inventors: Stephen T. Reeders, Karen E. Morrison, Billy G. Hudson
  • Advanced glycation end-product intermediaries and post-amadori inhibition
    Patent number: 5985857
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: November 16, 1999
    Assignee: Kansas University Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • .alpha.-3 chain type IV collagen polypeptides
    Patent number: 5973120
    Abstract: An isolated and substantially pure polynucleotide encoding 238 amino acids of the carboxy terminal end of the triple helical domain and all 233 amino acids of the carboxy terminal noncollageneous domain of the bovine .alpha.3 chain of type IV collagen. An isolated and substantially pure polynucleotide encoding 218 amino acids of the carboxy terminal noncollagenous domain of the human .alpha.3 chain of type IV collagen. Such polynucleotides are useful to express large amounts of proteins in vectors and such expressed proteins are useful to detect Goodpasture antibodies in blood and to remove Goodpasture antibodies from the bloodstream of patients suffering from Goodpasture syndrome.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: October 26, 1999
    Assignees: Yale University, University of Kansas Medical Center
    Inventors: Stephen T. Reeders, Karen E. Morrison, Billy G. Hudson
  • Isolated domains of type IV collagen to modify cell and tissue interactions
    Patent number: 5856184
    Abstract: The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: January 5, 1999
    Assignees: Yale University, University of Kansas Medical Center
    Inventors: Michael P. Sarras, Jr., Billy G. Hudson
  • Use of isolated domains of type IV collagen to modify cell and tissue interactions
    Patent number: 5691182
    Abstract: The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.
    Type: Grant
    Filed: June 30, 1995
    Date of Patent: November 25, 1997
    Assignee: University of Kansas Medical Center
    Inventors: Michael P. Sarras, Jr., Billy G. Hudson
  • Use of isolated domains of type IV collagen to modify cell and tissue interactions
    Patent number: 5567609
    Abstract: The instant invention demonstrates that the 7S and NC1 domains of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: October 22, 1996
    Assignee: University of Kansas Medical Center
    Inventors: Michael P. Sarras, Jr., Billy G. Hudson
  • .alpha.-3 chain type IV collagen polynucleotides
    Patent number: 5424408
    Abstract: An isolated and substantially pure polynucleotide encoding 238 amino acids of the carboxy terminal end of the triple helical domain and all 233 amino acids of the carboxy terminal noncollageneous domain of the bovine .alpha.3 chain of type IV collagen. An isolated and substantially pure polynucleotide encoding 218 amino acids of the carboxy terminal noncollagenous domain of the human .alpha.3 chain of type IV collagen. Such polynucleotides are useful to express large amounts of proteins in vectors and such expressed proteins are useful to detect Goodpasture antibodies in blood and to remove Goodpasture antibodies from the bloodstream of patients suffering from Goodpasture syndrome.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: June 13, 1995
    Assignees: Yale University, The University of Kansas Medical Center
    Inventors: Stephen T. Reeders, Karen E. Morrison, Billy G. Hudson